Immunotherapy company BioVaxys Technology Corp (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) reported on Wednesday that it has secured a Notice of Allowance from the United States Patent and Trademark Office for a patent enabling antibody immune response through low dose volume delivery of a B-cell epitope with its DPX formulation. This patent, part of BioVaxys' Intellectual Property portfolio, complements its existing international patent applications.
DPX, BioVaxys' lipid-based delivery platform, facilitates robust and sustained immune responses without an aqueous component. It can be combined with various antigens, proteins, peptides, mRNA, or small molecules, attracting antigen-presenting cells to the injection site for enhanced efficacy.
The company aims to deliver B-cell epitopes in doses as low as 50µL to 90 µL, significantly smaller than existing vaccine volumes. B-cell epitopes play a crucial role in activating the immune system's response against pathogens by binding to corresponding antigen receptors.
Additionally, BioVaxys has initiated the national phase for DPX SurMAGE, a dual-targeted immunotherapy formulation containing tumour-associated antigens survivin and MAGE A9. These antigens are prevalent in various cancers and represent promising targets for cancer vaccines.
Following a successful Phase I clinical study in Canada focusing on bladder cancer patients, DPX SurMAGE demonstrated a robust peptide-specific T cell response. The company plans further development in collaboration with clinical study investigators.
BioVaxys Technology Corp is dedicated to developing novel immunotherapies using its DPX immune-educating technology platform and HapTenix 'neoantigen' tumour cell construct platform. Its clinical pipeline includes maveropepimut-S and BVX-0918, targeting advanced cancers such as Relapsed-Refractory Diffuse Large B Cell Lymphoma and platinum-resistant ovarian cancer. Additionally, BioVaxys leverages its tumour immunology expertise to identify new targetable tumour antigens for personalized immunotherapeutic vaccines.
Gavi signs agreement with Bavarian Nordic for Mpox vaccines
Valneva seeks label extensions for chikungunya vaccine in Europe and Canada
MinervaX and Wacker Biotech collaborate on GBS vaccine manufacturing
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Pfizer names new Regional President for Middle East, Russia and Africa
LakeShore Biopharma names new chief executive officer
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Bavarian Nordic secures additional USD156.8m US government contract